The Association between <i>BRAF</i><sup>V600E</sup> Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis_West China Medical Journal

Authors：

 YangJing , YanShuping , GongYanping , ZhuJingqiang , LiZhihui ,  GongRixiang

Department of Thyroid and Breast Surgery,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P. R. China;

Corresponding?author：

GongRixiang, Email: gongrixiang@scu.edu.cn

Keywords：

BRAF^V600E; Papillary thyroid carcinoma; Clinicopathologic characteristics; Meta-analysis

DOI：

10.7507/1002-0179.201600127

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the frequency of BRAF^V600E mutation and the association between BRAF^V600Emutation and clinicopathologic characteristics of papillary thyroid carcinoma (PTC) in Chinese population by Meta-analysis. Methods The relevant published studies before January 2014 were reviewed according to the defined selection criteria using the PubMed,Embase,VIP,China Biology Medicine Database,Wanfang and China Knowledge Resource Integrated Database. The effect sizes of outcome parameters were estimated by odds ratio (OR) or weighted mean difference with a 95% confidence interval (CI). The quality of the included trials was assessed and Meta-analyses were conducted by RevMan 5.1 software. Results The study included 46 studies with a total of 5 831 patients. The prevalence of BRAF^V600E mutation ranged from 25% to 83%,with an overall prevalence of 54.6%. The clinicopathologic characteristics of 5 542 patients were analyzed. There were statistical significances in association between BRAF^V600E mutation and the presence of classical type [OR=2.30,95%CI (1.32,4.01),P=0.003],follicular type [OR=0.44,95%CI (0.23,0.86),P=0.02],extrathyroidal extension [OR=2.18,95%CI (1.83,2.59),P<0.00001],multifocality [OR=1.31,95%CI (1.07,1.60),P=0.009],lymphocytic thyroiditis [OR=0.31,95%CI (0.23,0.42),P<0.00001],lymph node metastasis [OR=1.95,95%CI (1.40,2.72),P<0.000 1],advanced TNM stage [OR=2.41,95%CI (2.01,2.88),P<0.00001] and recurrence [OR=3.22,95%CI (2.04,5.09),P<0.00001],but the correlation of BRAF^V600E mutation was not significant with gender,mean age,mean tumor size,age being ≥45 years,tumor size being ≥10 mm,tall cell type,and distant metastases (P>0.05). Conclusion In Chinese patients,PTC with BRAF^V600E mutation has more aggressive clinicopathologic characteristics than that without BRAF^V600E mutation. The BRAF^V600E mutation may be used as an important prognostic marker for patients with PTC.

Citation： YangJing, YanShuping, GongYanping, ZhuJingqiang, LiZhihui, GongRixiang. The Association between BRAF^V600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis. West China Medical Journal, 2016, 31(3): 467-479. doi: 10.7507/1002-0179.201600127 Copy

1.	Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2):245-262.
2.	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
3.	3 Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005[M/OL]. Bethesda:National Cancer Institute, 2007:907.[2010-12-24]. http://seer.cancer.gov/csr/1975_2005/.
4.	Schlumberger M, Pacini F. Prognostic factors[M]//Schlumberger M, Pacini F. Thyroid tumor. Paris:Nucleon Editions, 2003:111-125.
5.	Witt RL. Initial surgical management of thyroid cancer[J]. Surg Oncol Clin N Am, 2008, 17(1):71-91.
6.	Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid[J]. Endocr J, 2009, 56(2):177-192.
7.	Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002, 417(6892):949-954.
8.	Deluca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression[J]. Expert Rev Mol Med, 2008, 10(1):e6.
9.	Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population[J]. J Korean Med Sci, 2013, 28(4):534-541.
10.	Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J]. Ann Surg, 2007, 246(3):466-470; discussion 470-471.
11.	Kim TH, Park YJ, Lim JA, et al. The association of the BRAF^V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis[J]. Cancer, 2012, 118(7):1764-1773.
12.	Liu X, Yan K, Lin X, et al. The association between BRAF^V600E mutation and pathological features in PTC[J]. Eur Arch Otorhinolaryngol, 2014, 271(11):3041-3052.
13.	Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF^V600E mutation in papillary carcinomas of the thyroid:a meta-analysis[J]. Cancer, 2007, 110(1):38-46.
14.	Li C, Lee KC, Schneider EB, et al. BRAF^V600E mutation and its association with clinicopathological features of papillary thyroid cancer:a meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(12):4559-4570.
15.	Xing MZ, Clark D, Guan HX, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer[J]. J Clin Oncol, 2009, 27(18):2977-2982.
16.	Kim SJ, Lee KE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
17.	Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2008, 68(4):618-634.
18.	龔艷萍, 龔日祥, 楊敬, 等. 甲狀腺乳頭狀癌BRAF基因突變與臨床病理特征間的關系及臨床意義[J]. 四川大學學報:醫學版, 2013, 44(4):662-665.
19.	Nam JK, Jung CK, Song BJ, et al. Is the BRAF^V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer?[J]. Am J Surg, 2012, 203(4):436-441.
20.	Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAF^V600E mutation in papillary thyroid carcinoma[J]. World J Surg Oncol, 2013, 11:99.
21.	曾憲濤, 劉慧, 陳曦, 等. Meta分析系列之四:觀察性研究的質量評價工具[J]. 中國循證心血管醫學雜志, 2011, 8(4):297-299.
22.	龔日祥, 周揚, 羅書畫, 等. 甲狀腺乳頭狀癌BRAF基因突變的檢測及臨床意義[J]. 中華醫學遺傳學雜志, 2009, 26(3):310-313.
23.	Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan[J]. Clin Endocrinol (Oxf), 2005, 63(4):461-466.
24.	Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2009, 94(5):1612-1617.
25.	Shao H, Yu X, Wang C, et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer[J]. Endocrine, 2014, 46(2):285-291.
26.	尹香利, 張國昌, 李鋒, 等. MASA-PCR檢測甲狀腺乳頭狀癌中BRAF^V600E點突變的研究[J]. 石河子大學學報:自然科學版, 2005, 23(5):551-555.
27.	Gu LQ, Li FY, Zhao L, et al. BRAF^V600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma[J]. Thyroid, 2009, 19(4):347-354.
28.	Gong RX, Gong YP, Yang J, et al. Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography[J]. Genet Mol Res, 2013, 12(4):4990-4997.
29.	Gao WL, Wie LL, Chao YG, et al. Prognostic prediction of BRAF^V600E and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas[J]. Clin Lab, 2012, 58(9/10):919-926.
30.	Wang W, Zhao W, Wang H, et al. Poorer prognosis and higher prevalence of BRAF^V600E mutation in synchronous bilateral papillary thyroid carcinoma[J]. Ann Surg Oncol, 2012, 19(1):31-36.
31.	Jiang W, Wang W, Fu F, et al. A more sensitive platform for the detection of low-abundance BRAF^V600E mutations[J]. Mol Cell Biochem, 2012, 366(1/2):49-58.
32.	Zheng X, Xia T, Lin L, et al. BRAF^V600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma:experience of 512 cases at a clinical center in China[J]. World J Surg Oncol, 2012, 10:104.
33.	Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF^V600E mutational status in high aggressive papillary thyroid microcarcinoma[J]. Ann Surg Oncol, 2009, 16(2):240-245.
34.	Wang Y, Ji M, Wang W, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):183-190.
35.	Zhou YL, Liu C, Dai XX, et al. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas[J]. Med Oncol, 2012, 29(5):3360-3366.
36.	Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAF^V600E mutation[J]. Eur J Endocrinol, 2013, 168(5):675-681.
37.	Guan H, Ji M, Hou P, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer[J]. Cancer, 2008, 113(2):247-255.
38.	寶榮, 邵華, 成建新, 等. 甲狀腺乳頭狀癌中DNA修復基因hMLH1的甲基化與BRAF突變的關系[J]. 重慶醫學, 2010, 39(5):519-521.
39.	曹艷, 石光清, 向谷良. 甲狀腺癌中BRAF^V600E突變的表達及意義[J]. 放射免疫學雜志, 2011, 24(5):599-600, 封3.
40.	代文莉, 崔邦平, 胡濤, 等. 甲狀腺乳頭狀癌BRAF突變與初始治療療效的關系[J]. 現代腫瘤醫學, 2013, 21(3):504-506.
41.	戴詠玲, 李北寧, 努爾曼·麥麥提祖農, 等. BRAF基因突變與甲狀腺乳頭狀癌淋巴結轉移相關性的研究[J]. 中國醫學創新, 2011, 8(31):29-30.
42.	李小強, 張惠箴, 蔣智銘, 等. 甲狀腺乳頭狀癌中BRAF基因的表達及意義[J]. 臨床與實驗病理學雜志, 2012, 28(9):991-995.
43.	梁軍, 趙丹, 梁智勇, 等. 甲狀腺乳頭狀癌合并淋巴細胞性甲狀腺炎臨床病理生物學特征分析[J]. 中華腫瘤防治雜志, 2013, 20(17):1331-1335.
44.	劉超, 戴璇璇, 周毅力, 等. 甲狀腺乳頭狀癌mir-221表達與BRAF突變的相關性研究[J]. 中國腫瘤, 2012, 21(4):298-302.
45.	盧軍峰, 解乃昌, 姬逸男. BRAF^V600E基因突變及p27蛋白表達與甲狀腺乳頭狀癌頸淋巴結轉移的關系[J]. 河北醫學, 2011, 17(6):711-714.
46.	牛衛, 羅月球, 陳麗榮. 甲狀腺乳頭狀癌BRAF基因突變及表達的臨床意義研究[J]. 實用腫瘤雜志, 2008, 23(6):519-523.
47.	潘杰, 趙世華, 趙鵬, 等. 甲狀腺乳頭狀癌BRAF T1799A基因突變與血小板衍生生長因子關系的研究[J]. 現代腫瘤醫學, 2008, 16(9):1469-1472.
48.	濮亞斌, 李剛強. 甲狀腺乳頭狀癌中BRAF^V600E基因異常的臨床意義[J]. 實用癌癥雜志, 2013, 28(3):246-248.
49.	王煒, 黎向紅, 章銀輝, 等. BRAF基因V600E突變在甲狀腺病變中的表達[J]. 中華腫瘤雜志, 2011, 33(5):354-357.
50.	夏婷婷, 胡傳祥, 趙靜, 等. 甲狀腺乳頭狀癌BRAF^V600E突變分析[J]. 中國腫瘤臨床, 2012, 39(11):785-787.
51.	易文君, 鐘德玝, 鄒瓊燕. BRAF基因突變與甲狀腺乳頭狀癌的相關性[J]. 中南大學學報:醫學版, 2012, 37(4):370-373.
52.	Jing FJ, Liang J, Liang ZY, et al. BRAF^V600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma[J]. Chin Med J (Engl), 2013, 126(16):3013-3018.
53.	臧循雄, 陳建武, 林宏獻, 等. 甲狀腺乳頭狀癌BRAF^V600E基因突變的研究[J]. 現代實用醫學, 2009, 21(12):1296-1297, 1306, 封2.
54.	張薇, 王翠芳, 關海霞. 甲狀腺乳頭狀癌中M2型丙酮酸激酶的表達及其與BRAF基因突變的關系[J]. 腫瘤, 2013, 33(4):350-354.
55.	鄭麗, 胡向陽. Galectin-3、CK19、HBME-1表達和BRAF基因突變在甲狀腺乳頭狀癌中的意義[J]. 安徽西科大學學報, 2013, 48(4):401-405.
56.	周睿, 王偉斌, 王海勇, 等. RET/PTC、p53及BRAF在甲狀腺乳頭狀癌中的表達和意義[J]. 浙江醫學, 2010, 32(6):942-944.
57.	朱曉麗, 周曉燕, 朱雄增. 甲狀腺乳頭狀癌中BRAF^V600E點突變與RET/PTC融合基因的檢測[J]. 中華病理學雜志, 2005, 34(5):270-274.
58.	左慶瑤, 高燕明, 劉寶岳, 等. 乳頭狀甲狀腺癌BRAF^V600E突變的表達和意義[J]. 中華內科雜志, 2009, 48(5):412-413.
59.	鄭向前, 夏婷婷, 林琳, 等. 多灶性甲狀腺乳頭狀癌BRAF^V600E基因突變及臨床生物學特性分析[J]. 中國腫瘤臨床, 2011, 38(21):1326-1329.
60.	亓龍, 左娣, 王輝, 等. REGγ、p53、NOTCH1和BRAF在甲狀腺癌中的表達及其臨床意義[J]. 華東師范大學學報:自然科學版, 2012(6):89-95.
61.	趙洪濤, 趙春清, 張彬, 等. 甲狀腺乳頭狀癌中CD44v6 BRAF和Rasp21的表達[J]. 中國腫瘤臨床與康復, 2012, 19(4):310-312.
62.	高衛利, 王偉斌, 王浩浩, 等. 甲狀腺乳頭狀癌BRAF^V600E突變和鈉/碘轉運體表達的研究[J]. 中華普通外科雜志, 2013, 28(5):378-381.
63.	江曉燊, 解乃昌. 甲狀腺乳頭狀癌BRAF^V600E突變蛋白質的表達及意義[J]. 廣東醫學, 2013, 34(6):931-933.
64.	李志鋒, 劉進忠, 孫鵬娟, 等. HIF-1α、BRAF、S100A6在甲狀腺乳頭狀癌中的表達及其臨床意義[J]. 臨床外科雜志, 2013, 21(6):436-438.
65.	劉友忠, 于洋, 趙翠, 等. 甲狀腺乳頭狀癌合并橋本甲狀腺炎的臨床生物學特性分析[J]. 中華普通外科雜志, 2013, 28(4):256-258.
66.	王昊, 盧瑞春, 董嫻寧, 等. BRAF基因V600E突變與Ⅰ~Ⅱ期乳頭狀甲狀腺癌臨床病理特征及預后的相關性分析[J]. 臨床腫瘤學雜志, 2013, 18(12):1100-1103.
67.	運新偉, 劉友忠, 高明. 甲狀腺乳頭狀癌合并橋本甲狀腺炎的臨床特征與BRAF^V600E基因突變的相關性分析[J]. 中華內分泌代謝雜志, 2013, 29(11):931-934.
68.	鐘文昭, 吳一龍, 谷力加. Review Manager(RevMan)——臨床醫生通向Meta分析的橋梁[J]. 循證醫學, 2003, 3(4):234-246.
69.	Frasca F, Nucera C, Pellegriti G, et al. BRAF^V600E mutation and the biology of papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):191-205.
70.	Stanojevic B, Dzodic R, Saenko V, et al. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia[J]. Endocr J, 2011, 58(5):381-393.
71.	Elisei R, Ugolini C, Viola D, et al. BRAF^V600E mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
72.	Sykorova V, Dvorakova S, Ryska A, et al. BRAF^V600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic[J]. J Endocrinol Invest, 2010, 33(5):318-324.
73.	Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population:its lack of correlation with high-risk clinicopathological features and disease-free survival of patients[J]. Endocr J, 2009, 56(1):89-97.
74.	Kurtulmus N, Duren M, Ince U, et al. BRAF^V600E mutation in Turkish patients with papillary thyroid cancer:strong correlation with indicators of tumor aggressiveness[J]. Endocrine, 2012, 42(2):404-410.
75.	Kim SJ, Ke LE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
76.	Jo YS, Li S, Song JH, et al. Influence of the BRAF^V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2006, 91(9):3667-3670.
77.	Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population[J]. Yonsei Med J, 2004, 45(5):818-821.
78.	Finkelstein A, Levy GH, Hui P, et al. Papillary thyroid carcinomas with and without BRAF^V600E mutations are morphologically distinct[J]. Histopathology, 2012, 60(7):1052-1059.
79.	Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?[J]. Surgery, 2012, 152(6):977-982.
80.	Morris LG, Shaha AR, Tuttle RM, et al. Tall-cell variant of papillary thyroid carcinoma:a matched-pair analysis of survival[J]. Thyroid, 2010, 20(2):153-158.
81.	Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma[J]. Laryngoscope, 2008, 118(1):32-38.
82.	Lang BH, Lo CY, Chan WF, et al. Classical and follicular variant of papillary thyroid carcinoma:a comparative study on clinicopathologic features and long-term outcome[J]. World J Surg, 2006, 30(5):752-758.
83.	Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012, 91(5):274-286.
84.	Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF^V600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid, 2009, 19(2):137-141.
85.	Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-773; discussion 773-775.
86.	Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis:a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3):343-349.
87.	Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2006, 65(3):364-368.
88.	Lee JI, Jang HW, Kim SW, et al. BRAF^V600E mutation in fine-needle aspiration aspirates:association with poorer prognostic factors in larger papillary thyroid carcinomas[J]. Head Neck, 2013, 35(4):548-553.
89.	Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAF^V600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval[J]. Clin Endocrinol (Oxf), 2012, 77(5):780-786.
90.	Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428.
91.	Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment:initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group[J]. Cancer, 1998, 83(5):1012-1021.
92.	Xing M. BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications[J]. Endocr Rev, 2007, 28(7):742-762.
93.	Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis[J]. J Clin Endocrinol Metab, 2005, 90(10):5723-5729.
94.	Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma[J]. Surgery, 2008, 144(6):1070-1077; discussion 1077-1078.
95.	Lupi C, Giannini R, Ugolini C, et al. Association of BRAF^V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2007, 92(11):4085-4090.

1. Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2):245-262.
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
3. 3 Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005[M/OL]. Bethesda:National Cancer Institute, 2007:907.[2010-12-24]. http://seer.cancer.gov/csr/1975_2005/.
4. Schlumberger M, Pacini F. Prognostic factors[M]//Schlumberger M, Pacini F. Thyroid tumor. Paris:Nucleon Editions, 2003:111-125.
5. Witt RL. Initial surgical management of thyroid cancer[J]. Surg Oncol Clin N Am, 2008, 17(1):71-91.
6. Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid[J]. Endocr J, 2009, 56(2):177-192.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002, 417(6892):949-954.
8. Deluca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression[J]. Expert Rev Mol Med, 2008, 10(1):e6.
9. Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population[J]. J Korean Med Sci, 2013, 28(4):534-541.
10. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J]. Ann Surg, 2007, 246(3):466-470; discussion 470-471.
11. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF^V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis[J]. Cancer, 2012, 118(7):1764-1773.
12. Liu X, Yan K, Lin X, et al. The association between BRAF^V600E mutation and pathological features in PTC[J]. Eur Arch Otorhinolaryngol, 2014, 271(11):3041-3052.
13. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF^V600E mutation in papillary carcinomas of the thyroid:a meta-analysis[J]. Cancer, 2007, 110(1):38-46.
14. Li C, Lee KC, Schneider EB, et al. BRAF^V600E mutation and its association with clinicopathological features of papillary thyroid cancer:a meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(12):4559-4570.
15. Xing MZ, Clark D, Guan HX, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer[J]. J Clin Oncol, 2009, 27(18):2977-2982.
16. Kim SJ, Lee KE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
17. Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2008, 68(4):618-634.
18. 龔艷萍, 龔日祥, 楊敬, 等. 甲狀腺乳頭狀癌BRAF基因突變與臨床病理特征間的關系及臨床意義[J]. 四川大學學報:醫學版, 2013, 44(4):662-665.
19. Nam JK, Jung CK, Song BJ, et al. Is the BRAF^V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer?[J]. Am J Surg, 2012, 203(4):436-441.
20. Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAF^V600E mutation in papillary thyroid carcinoma[J]. World J Surg Oncol, 2013, 11:99.
21. 曾憲濤, 劉慧, 陳曦, 等. Meta分析系列之四:觀察性研究的質量評價工具[J]. 中國循證心血管醫學雜志, 2011, 8(4):297-299.
22. 龔日祥, 周揚, 羅書畫, 等. 甲狀腺乳頭狀癌BRAF基因突變的檢測及臨床意義[J]. 中華醫學遺傳學雜志, 2009, 26(3):310-313.
23. Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan[J]. Clin Endocrinol (Oxf), 2005, 63(4):461-466.
24. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2009, 94(5):1612-1617.
25. Shao H, Yu X, Wang C, et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer[J]. Endocrine, 2014, 46(2):285-291.
26. 尹香利, 張國昌, 李鋒, 等. MASA-PCR檢測甲狀腺乳頭狀癌中BRAF^V600E點突變的研究[J]. 石河子大學學報:自然科學版, 2005, 23(5):551-555.
27. Gu LQ, Li FY, Zhao L, et al. BRAF^V600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma[J]. Thyroid, 2009, 19(4):347-354.
28. Gong RX, Gong YP, Yang J, et al. Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography[J]. Genet Mol Res, 2013, 12(4):4990-4997.
29. Gao WL, Wie LL, Chao YG, et al. Prognostic prediction of BRAF^V600E and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas[J]. Clin Lab, 2012, 58(9/10):919-926.
30. Wang W, Zhao W, Wang H, et al. Poorer prognosis and higher prevalence of BRAF^V600E mutation in synchronous bilateral papillary thyroid carcinoma[J]. Ann Surg Oncol, 2012, 19(1):31-36.
31. Jiang W, Wang W, Fu F, et al. A more sensitive platform for the detection of low-abundance BRAF^V600E mutations[J]. Mol Cell Biochem, 2012, 366(1/2):49-58.
32. Zheng X, Xia T, Lin L, et al. BRAF^V600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma:experience of 512 cases at a clinical center in China[J]. World J Surg Oncol, 2012, 10:104.
33. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF^V600E mutational status in high aggressive papillary thyroid microcarcinoma[J]. Ann Surg Oncol, 2009, 16(2):240-245.
34. Wang Y, Ji M, Wang W, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):183-190.
35. Zhou YL, Liu C, Dai XX, et al. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas[J]. Med Oncol, 2012, 29(5):3360-3366.
36. Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAF^V600E mutation[J]. Eur J Endocrinol, 2013, 168(5):675-681.
37. Guan H, Ji M, Hou P, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer[J]. Cancer, 2008, 113(2):247-255.
38. 寶榮, 邵華, 成建新, 等. 甲狀腺乳頭狀癌中DNA修復基因hMLH1的甲基化與BRAF突變的關系[J]. 重慶醫學, 2010, 39(5):519-521.
39. 曹艷, 石光清, 向谷良. 甲狀腺癌中BRAF^V600E突變的表達及意義[J]. 放射免疫學雜志, 2011, 24(5):599-600, 封3.
40. 代文莉, 崔邦平, 胡濤, 等. 甲狀腺乳頭狀癌BRAF突變與初始治療療效的關系[J]. 現代腫瘤醫學, 2013, 21(3):504-506.
41. 戴詠玲, 李北寧, 努爾曼·麥麥提祖農, 等. BRAF基因突變與甲狀腺乳頭狀癌淋巴結轉移相關性的研究[J]. 中國醫學創新, 2011, 8(31):29-30.
42. 李小強, 張惠箴, 蔣智銘, 等. 甲狀腺乳頭狀癌中BRAF基因的表達及意義[J]. 臨床與實驗病理學雜志, 2012, 28(9):991-995.
43. 梁軍, 趙丹, 梁智勇, 等. 甲狀腺乳頭狀癌合并淋巴細胞性甲狀腺炎臨床病理生物學特征分析[J]. 中華腫瘤防治雜志, 2013, 20(17):1331-1335.
44. 劉超, 戴璇璇, 周毅力, 等. 甲狀腺乳頭狀癌mir-221表達與BRAF突變的相關性研究[J]. 中國腫瘤, 2012, 21(4):298-302.
45. 盧軍峰, 解乃昌, 姬逸男. BRAF^V600E基因突變及p27蛋白表達與甲狀腺乳頭狀癌頸淋巴結轉移的關系[J]. 河北醫學, 2011, 17(6):711-714.
46. 牛衛, 羅月球, 陳麗榮. 甲狀腺乳頭狀癌BRAF基因突變及表達的臨床意義研究[J]. 實用腫瘤雜志, 2008, 23(6):519-523.
47. 潘杰, 趙世華, 趙鵬, 等. 甲狀腺乳頭狀癌BRAF T1799A基因突變與血小板衍生生長因子關系的研究[J]. 現代腫瘤醫學, 2008, 16(9):1469-1472.
48. 濮亞斌, 李剛強. 甲狀腺乳頭狀癌中BRAF^V600E基因異常的臨床意義[J]. 實用癌癥雜志, 2013, 28(3):246-248.
49. 王煒, 黎向紅, 章銀輝, 等. BRAF基因V600E突變在甲狀腺病變中的表達[J]. 中華腫瘤雜志, 2011, 33(5):354-357.
50. 夏婷婷, 胡傳祥, 趙靜, 等. 甲狀腺乳頭狀癌BRAF^V600E突變分析[J]. 中國腫瘤臨床, 2012, 39(11):785-787.
51. 易文君, 鐘德玝, 鄒瓊燕. BRAF基因突變與甲狀腺乳頭狀癌的相關性[J]. 中南大學學報:醫學版, 2012, 37(4):370-373.
52. Jing FJ, Liang J, Liang ZY, et al. BRAF^V600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma[J]. Chin Med J (Engl), 2013, 126(16):3013-3018.
53. 臧循雄, 陳建武, 林宏獻, 等. 甲狀腺乳頭狀癌BRAF^V600E基因突變的研究[J]. 現代實用醫學, 2009, 21(12):1296-1297, 1306, 封2.
54. 張薇, 王翠芳, 關海霞. 甲狀腺乳頭狀癌中M2型丙酮酸激酶的表達及其與BRAF基因突變的關系[J]. 腫瘤, 2013, 33(4):350-354.
55. 鄭麗, 胡向陽. Galectin-3、CK19、HBME-1表達和BRAF基因突變在甲狀腺乳頭狀癌中的意義[J]. 安徽西科大學學報, 2013, 48(4):401-405.
56. 周睿, 王偉斌, 王海勇, 等. RET/PTC、p53及BRAF在甲狀腺乳頭狀癌中的表達和意義[J]. 浙江醫學, 2010, 32(6):942-944.
57. 朱曉麗, 周曉燕, 朱雄增. 甲狀腺乳頭狀癌中BRAF^V600E點突變與RET/PTC融合基因的檢測[J]. 中華病理學雜志, 2005, 34(5):270-274.
58. 左慶瑤, 高燕明, 劉寶岳, 等. 乳頭狀甲狀腺癌BRAF^V600E突變的表達和意義[J]. 中華內科雜志, 2009, 48(5):412-413.
59. 鄭向前, 夏婷婷, 林琳, 等. 多灶性甲狀腺乳頭狀癌BRAF^V600E基因突變及臨床生物學特性分析[J]. 中國腫瘤臨床, 2011, 38(21):1326-1329.
60. 亓龍, 左娣, 王輝, 等. REGγ、p53、NOTCH1和BRAF在甲狀腺癌中的表達及其臨床意義[J]. 華東師范大學學報:自然科學版, 2012(6):89-95.
61. 趙洪濤, 趙春清, 張彬, 等. 甲狀腺乳頭狀癌中CD44v6 BRAF和Rasp21的表達[J]. 中國腫瘤臨床與康復, 2012, 19(4):310-312.
62. 高衛利, 王偉斌, 王浩浩, 等. 甲狀腺乳頭狀癌BRAF^V600E突變和鈉/碘轉運體表達的研究[J]. 中華普通外科雜志, 2013, 28(5):378-381.
63. 江曉燊, 解乃昌. 甲狀腺乳頭狀癌BRAF^V600E突變蛋白質的表達及意義[J]. 廣東醫學, 2013, 34(6):931-933.
64. 李志鋒, 劉進忠, 孫鵬娟, 等. HIF-1α、BRAF、S100A6在甲狀腺乳頭狀癌中的表達及其臨床意義[J]. 臨床外科雜志, 2013, 21(6):436-438.
65. 劉友忠, 于洋, 趙翠, 等. 甲狀腺乳頭狀癌合并橋本甲狀腺炎的臨床生物學特性分析[J]. 中華普通外科雜志, 2013, 28(4):256-258.
66. 王昊, 盧瑞春, 董嫻寧, 等. BRAF基因V600E突變與Ⅰ~Ⅱ期乳頭狀甲狀腺癌臨床病理特征及預后的相關性分析[J]. 臨床腫瘤學雜志, 2013, 18(12):1100-1103.
67. 運新偉, 劉友忠, 高明. 甲狀腺乳頭狀癌合并橋本甲狀腺炎的臨床特征與BRAF^V600E基因突變的相關性分析[J]. 中華內分泌代謝雜志, 2013, 29(11):931-934.
68. 鐘文昭, 吳一龍, 谷力加. Review Manager(RevMan)——臨床醫生通向Meta分析的橋梁[J]. 循證醫學, 2003, 3(4):234-246.
69. Frasca F, Nucera C, Pellegriti G, et al. BRAF^V600E mutation and the biology of papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1):191-205.
70. Stanojevic B, Dzodic R, Saenko V, et al. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia[J]. Endocr J, 2011, 58(5):381-393.
71. Elisei R, Ugolini C, Viola D, et al. BRAF^V600E mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
72. Sykorova V, Dvorakova S, Ryska A, et al. BRAF^V600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic[J]. J Endocrinol Invest, 2010, 33(5):318-324.
73. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population:its lack of correlation with high-risk clinicopathological features and disease-free survival of patients[J]. Endocr J, 2009, 56(1):89-97.
74. Kurtulmus N, Duren M, Ince U, et al. BRAF^V600E mutation in Turkish patients with papillary thyroid cancer:strong correlation with indicators of tumor aggressiveness[J]. Endocrine, 2012, 42(2):404-410.
75. Kim SJ, Ke LE, Myong JP, et al. BRAF^V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2):310-317.
76. Jo YS, Li S, Song JH, et al. Influence of the BRAF^V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2006, 91(9):3667-3670.
77. Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population[J]. Yonsei Med J, 2004, 45(5):818-821.
78. Finkelstein A, Levy GH, Hui P, et al. Papillary thyroid carcinomas with and without BRAF^V600E mutations are morphologically distinct[J]. Histopathology, 2012, 60(7):1052-1059.
79. Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?[J]. Surgery, 2012, 152(6):977-982.
80. Morris LG, Shaha AR, Tuttle RM, et al. Tall-cell variant of papillary thyroid carcinoma:a matched-pair analysis of survival[J]. Thyroid, 2010, 20(2):153-158.
81. Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma[J]. Laryngoscope, 2008, 118(1):32-38.
82. Lang BH, Lo CY, Chan WF, et al. Classical and follicular variant of papillary thyroid carcinoma:a comparative study on clinicopathologic features and long-term outcome[J]. World J Surg, 2006, 30(5):752-758.
83. Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012, 91(5):274-286.
84. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF^V600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid, 2009, 19(2):137-141.
85. Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-773; discussion 773-775.
86. Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis:a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3):343-349.
87. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2006, 65(3):364-368.
88. Lee JI, Jang HW, Kim SW, et al. BRAF^V600E mutation in fine-needle aspiration aspirates:association with poorer prognostic factors in larger papillary thyroid carcinomas[J]. Head Neck, 2013, 35(4):548-553.
89. Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAF^V600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval[J]. Clin Endocrinol (Oxf), 2012, 77(5):780-786.
90. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428.
91. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment:initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group[J]. Cancer, 1998, 83(5):1012-1021.
92. Xing M. BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications[J]. Endocr Rev, 2007, 28(7):742-762.
93. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis[J]. J Clin Endocrinol Metab, 2005, 90(10):5723-5729.
94. Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma[J]. Surgery, 2008, 144(6):1070-1077; discussion 1077-1078.
95. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF^V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2007, 92(11):4085-4090.

West China Medical Journal

The Association between BRAF^V600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

West China Medical Journal

The Association between BRAFV600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

The Association between BRAF^V600E Mutation and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Chinese Population: A Meta-analysis